Brief: Keymed, Lepu Biopharma Jointly Announce Global Exclusive Licence Agreement With Astrazeneca For CMG901

Lepu Biopharma

23/02/2023 05:14

Feb 23 (Reuters) - Lepu Biopharma Co Ltd  2157.HK :
    * KEYMED AND LEPU BIOPHARMA JOINTLY ANNOUNCE GLOBAL
EXCLUSIVE
LICENCE AGREEMENT WITH ASTRAZENECA FOR CMG901
    * KEYMED - UNDER LICENCE AGREEMENT, ASTRAZENECA WILL BE
RESPONSIBLE FOR THE RESEARCH, DEVELOPMENT, MANUFACTURE AND
COMMERCIALISATION OF  CMG901 GLOBALLY
    * KEYMED - PRELIMINARY RESULTS FROM THE PHASE 1 TRIAL
INDICATED
THAT CMG901 HAS A FAVORABLE SAFETY AND TOLERABILITY PROFILE
    * KEYMED - JOINT VENTURE ESTABLISHED BY KEYMED AND LEPU
BIOPHARMA,
WILL RECEIVE AN UPFRONT PAYMENT OF $63M ON TRANSACTION CLOSING
    * KEYMED - ADDITIONAL DEVELOPMENT AND SALES-RELATED
MILESTONE
PAYMENTS OF UP TO $1.1BN AS WELL AS TIERED ROYALTIES UP TO LOW
DOUBLE-DIGITS

Source text for Eikon:  ID:nPn5p4ydha 
Further company coverage:  2157.HK 
 ((Reuters.Briefs@thomsonreuters.com;))